Tibau A, Hwang T, Avorn J, Kesselheim A
BMJ. 2024; 386:e079126.
PMID: 39164034
PMC: 11333991.
DOI: 10.1136/bmj-2023-079126.
Ding L, Yuan X, Wang Y, Shen Z, Wu P
BMJ Open. 2024; 14(6):e077108.
PMID: 38851227
PMC: 11163648.
DOI: 10.1136/bmjopen-2023-077108.
Tibau A, Hwang T, Molto C, Avorn J, Kesselheim A
JAMA Oncol. 2024; 10(5):634-641.
PMID: 38573645
PMC: 11099684.
DOI: 10.1001/jamaoncol.2024.0194.
Nadler M, Wilson B, Desnoyers A, Valiente C, Saleh R, Amir E
Sci Rep. 2024; 14(1):459.
PMID: 38172190
PMC: 10764749.
DOI: 10.1038/s41598-023-50694-0.
Mulder J, Teerenstra S, van Hennik P, Pasmooij A, Stoyanova-Beninska V, Voest E
ESMO Open. 2023; 8(2):101209.
PMID: 37054504
PMC: 10163162.
DOI: 10.1016/j.esmoop.2023.101209.
Analysis of oncological drugs authorised in Spain in the last decade: association between clinical benefit and reimbursement.
Nieto-Gomez P, Castano-Amores C, Rodriguez-Delgado A, Alvarez-Sanchez R
Eur J Health Econ. 2023; 25(2):257-267.
PMID: 36995531
DOI: 10.1007/s10198-023-01584-9.
Association between control group therapy and magnitude of clinical benefit of cancer drugs.
Molto C, Tibau A, Bujosa A, Tapia J, Mittal A, Tamimi F
Sci Rep. 2022; 12(1):21342.
PMID: 36494465
PMC: 9734169.
DOI: 10.1038/s41598-022-25983-9.
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia.
Hwang T, Kesselheim A, Tibau A, Lee C, Vokinger K
JCO Oncol Pract. 2022; 18(9):e1522-e1532.
PMID: 35731996
PMC: 9509186.
DOI: 10.1200/OP.21.00909.
Trends in Phase II Trials for Cancer Therapies.
Azam F, Vazquez A
Cancers (Basel). 2021; 13(2).
PMID: 33430223
PMC: 7825663.
DOI: 10.3390/cancers13020178.
Associations between safety, tolerability, and toxicity and the reporting of health-related quality of life in phase III randomized trials in common solid tumors.
Saleh R, Meti N, Ribnikar D, Goldvaser H, Ocana A, Templeton A
Cancer Med. 2020; 9(21):7888-7895.
PMID: 32886422
PMC: 7643655.
DOI: 10.1002/cam4.3390.
Evidence-Based Medicine in Oncology: Commercial Versus Patient Benefit.
Schirrmacher V, Sprenger T, Stuecker W, Van Gool S
Biomedicines. 2020; 8(8).
PMID: 32717895
PMC: 7460025.
DOI: 10.3390/biomedicines8080237.
Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
Mulinari S, Vilhelmsson A, Rickard E, Ozieranski P
PLoS One. 2020; 15(6):e0235021.
PMID: 32579571
PMC: 7313941.
DOI: 10.1371/journal.pone.0235021.
Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration.
Hilal T, Gonzalez-Velez M, Prasad V
JAMA Intern Med. 2020; 180(8):1108-1115.
PMID: 32539071
PMC: 7296449.
DOI: 10.1001/jamainternmed.2020.2250.
Required efficacy for novel therapies in BCG-unresponsive non-muscle invasive bladder cancer: Do current recommendations really reflect clinically meaningful outcomes?.
Wettstein M, Naimark D, Hermanns T, Herrera-Caceres J, Ahmad A, Jewett M
Cancer Med. 2020; 9(10):3287-3296.
PMID: 32163677
PMC: 7221312.
DOI: 10.1002/cam4.2980.
Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis.
Naci H, Davis C, Savovic J, Higgins J, Sterne J, Gyawali B
BMJ. 2019; 366:l5221.
PMID: 31533922
PMC: 6749182.
DOI: 10.1136/bmj.l5221.
